Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets

Thrombosis and Haemostasis

Volumn 109, Issue 6, 2013, Pages 1016-1024

  Stevic, Ivan ^a,b   Chan, Howard H W ^a,b   Chander, Ankush ^a,b   Berry, Leslie R ^a,b   Chan, Anthony K C ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Coagulation; Covalent antithrombin heparin; Heparin; Platelets; Pro thrombinase complex

Indexed keywords

ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; CALCIMYCIN; CALCIUM; ENOXAPARIN; FLUORESCEIN ISOTHIOCYANATE; FONDAPARINUX; HEPARIN; PROTHROMBIN; THROMBIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; COVALENT BOND; ENZYME INHIBITION; FLOW CYTOMETRY; HALF LIFE TIME; HUMAN; HUMAN CELL; PLATELET MICROPARTICLE; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE ACTIVATION; TURBIDIMETRY;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD PLATELETS; ENZYME INHIBITORS; FACTOR XA; FLOW CYTOMETRY; HEPARIN; HUMANS; NEPHELOMETRY AND TURBIDIMETRY; PLATELET ACTIVATION; PROTEIN BINDING; THROMBOPLASTIN;

EID: 84878664615     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0766     Document Type: Article

References (41)

1. Suttie J W, Jackson CM. Prothrombin structure, activation and biosynthesis. Physiol Rev 1977; 57: 1-70.
2. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and Factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-10962.
3. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 1988; 57: 915-956.
4. Kalafatis M, Swords NA, Rand MD, et al. Membrane-dependent reactions in blood coagulation: role of the vitamin k-dependent enzyme complexes. Bio-chem Biophys Acta 1994; 1227: 113-119.
5. Wilkens M, Krishnaswamy S. The contribution of factor Xa to exosite-depend-ent substrate recognition by prothrombinase. J Biol Chem 2002; 277: 9366-9374.
6. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370.
7. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-357.
8. Olds RJ, Lane DA, Mille B, et al. Antithrombin: the principal inhibitor of throm-bin. Semin Thromb Hemost 1994; 20: 353-372.
9. Jin L, Abrahams J P, Skinner R, et al. The anticoagulant activation of antithrom-bin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
10. Hatton MWC, Berry LR, Machovich R, et al. Titration of commercial heparins by reaction with NaB3WH4: chemical analysis and biological properties of the product. Analyt Biochem 1980; 106: 417-426.
11. Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001; 21: 1094-1096.
12. Hoylaerts M, Owen WG, Collen D. Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III. J Biol Chem 1984; 259: 5670-5677.
13. Hirsh J, Bates SM. Clinical trials that have influenced the treatment of venous thromboembolism: A historical perspective. Ann Intern Med 2001; 134: 409-417.
14. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight haprin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
15. Boneu S, Caranobe C, Gabaig AM, et al. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res 1987; 46: 835-844.
16. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-1478.
17. Marciniak E. Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabalization of factor Xa by factor V-phospholipid complex. Br J Haematol 1973; 24: 391-400.
18. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by heparin-antithrombin complex. Blood 2001; 97: 2308-2313.
19. Bruffato N, Ward A, Nesheim ME. Factor Xa is highly protected from anti-thrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258-1263.
20. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by hepa-rin-antithrombin complex. J Clin Invest 1983; 71: 1383-1391.
21. Schoen P, Lindhout T, Willems G, Hemker C. Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. J Biol Chem 1989; 264: 10002-10007.
22. Ellis V, Scully M F, Kakkar V V. The acceleration of the inhibition of platelet pro-thrombinase by heparin. Biochem J 1986; 233: 161-165.
23. Barrowcliffe T W, Havercroft SJ, Kemball-Cook G, et al. The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides. Biochem J 1987; 243: 31-37.
24. Stevic I, Berry LR, Chan AKC. Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex. J Biochem 2012; 152: 139-148.
25. Chan AKC, Berry LR, O'brodovich H, et al. Covalent antithrombin-heparin complexes with high anticoagulant activity: Intravenous, subcutaneous, and in-tratracheal administration. J Biol Chem 1997; 272: 22111-22117.
26. Parmar N, Berry LR, Post M, et al. Effect of covalent antithrombin-heparin complex on developmental mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2009; 296: L394-L403.
27. Smith LJ, Mewhort-Buist TA, Berry LR, Chan AKC. An antithrombin-heparin complex increases the anticoagulant activity of fibrin clots. Res Lett Biochem 2008; 2008: 639829.
28. Patel S, Berry LR, Chan AKC. Analysis of inhibition rate enhancement by coval-ent linkage of antithrombin to heparin as a potential predictor reaction mechanism. J Biochem 2007; 141: 25-35.
29. Klement P, Berry LR, Liao P, et al. Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. Blood 21010; 116: 5716-5723.
30. Chan AKC, Rak J, Berry LR, et al. Antithrombin-heparin covalent complex: A possible alternative to heparin for arterial thrombosis prevention. Circulation 2002; 106: 261-265.
31. Paredes N, Wang A, Berry LR, et al. Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrom-bin-heparin complex. J Biol Chem 2003; 278: 23398-23409.
32. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by anti-thrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
33. Gaffet P, Bettache N, Bienvenue A. Phosphatidylserine exposure on the platelet plasma membrane during A23187-induced activation is independent of cytos-keleton reorganization. Eur J Cell Biol 1995; 67: 336-345.
34. Wood J, Silveira JR, Maille NM, et al. Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity. Blood 2011; 117: 1710-1718.
35. Rosing J, Zwaal RFA, Tans G. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation. J Biol Chem 1986; 261: 4224-4228.
36. Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem 1986; 261: 8977-8984.
37. Lindhout T, Baruch D, Schoen P, et al. Thrombin generation and inactivation in the presence of antithrombin III and heparin. Biochemistry 1986; 25: 5962-5969.
38. Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and he-parin. Glycobiology 1993; 3: 271-277.
39. Francis JL. Detection and significance of heparin-platelet factor 4 antibodies. Semin Hematol 2005; 42: S9-S14.
40. Krauel K, Hackbarth C, Furll B, et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated he-parin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012; 119: 1248-1255.
41. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 2004; 110: e454-e458.